Detalles de la búsqueda
1.
The Short-Term Cost-Effectiveness of a Fixed-Ratio Combination of Insulin Degludec and Aspart: A Cost of Control Analysis in Australia and India.
Value Health Reg Issues
; 41: 108-113, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38320441
2.
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
BMJ Open
; 13(9): e070473, 2023 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775297
3.
Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Diabetes Ther
; 10(4): 1297-1317, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31098942
4.
Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Diabetes Ther
; 10(4): 1319-1321, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31152431
Resultados
1 -
4
de 4
1
Próxima >
>>